• Margot Denier, Sarah Tick, Romain Dubois, Remy Dulery, Andrew W Eller, Felipe Suarez, Barbara Burroni, Claude-Alain Maurage, Claire Bories, Johanna Konopacki, Michel Puech, Didier Bouscary, Alberte Cantalloube, Emmanuel Héron, Ambroise Marçais, Christophe Habas, Vincent Theillac, Chafik Keilani, Gabrielle R Bonhomme, Denise S Gallagher, Julien Boumendil, Wajed Abarah, Neila Sedira, Stéphane Bertin, Sylvain Choquet, José-Alain Sahel, Lilia Merabet, Françoise Brignole-Baudouin, Marc Putterman, and Marie-Hélène Errera.
• Centre Hospitalier National des Quinze-Vingts, CIC 1423, DHU Sight Restore, 28 rue de Charenton, Sorbonne-Universités, Université Pierre et Marie Curie (UPMC), 75012 Paris, France.
• Medicina (Kaunas). 2022 Mar 21; 58 (3).

AbstractBackground and Objectives: Secondary ocular localizations of hematological malignancies are blinding conditions with a poor prognosis, and often result in a delay in the diagnosis. Materials and Methods: We describe a series of rare cases of ocular involvement in six patients with hematological malignancies, reportedly in remission, who presented secondary ocular localizations, challenging to diagnose. Two patients had an acute lymphoblastic leukemia (ALL) and developed either a posterior scleritis or a pseudo-panuveitis with ciliary process infiltration. One patient had iris plasmacytoma and developed an anterior uveitis as a secondary presentation. Two patients had a current systemic diffuse large B-cell lymphoma (DLBCL) and were referred either for intermediate uveitis or for papilledema and vitritis with secondary retinitis. Finally, one patient with an acute myeloid leukemia (AML) presented a conjunctival localization of a myeloid sarcoma. We herein summarize the current knowledge of ophthalmologic manifestations of extramedullary hematopathies. Results: Inflammatory signs were associated with symptomatic infiltrative lesions well displayed in either the iris, the retina, the choroid, or the cavernous sinus, from the admission of the patients in the ophthalmological department. These findings suggest that patients with ALL, AML, systemic DLBCL, and myeloma can present with ophthalmic involvement, even after having been reported as in remission following an effective systemic treatment and/or allograft. Conclusions: Early detection of hidden recurrence in the eyes may permit effective treatment. Furthermore, oncologists and ophthalmologists should be aware of those rare ocular malignant locations when monitoring patient's progression after initial treatment, and close ophthalmologic examinations should be recommended when detecting patient's ocular symptoms after treatment.

10 keywords...

hide…